Associations - FGFR3 Y373C

BIOMARKER:

FGFR3 Y373C

Entrez ID:

Related biomarkers:

‹

›

VERI is free for non-commercial use, no login needed.

Content on this site is for research purposes only and is not intended to be a substitute for medical advice.

For commercial access, including additional premium features, please contact us.

By using VERI, you are agreeing to our

and

VERI is free for non-commercial use, no login needed.

Content on this site is for research purposes only and is not intended to be a substitute for medical advice.

For commercial access, including additional premium features, please contact us.

By using VERI, you are agreeing to our

and

VERI is free for non-commercial use, no login needed.

Content on this site is for research purposes only and is not intended to be a substitute for medical advice.

For commercial access, including additional premium features, please contact us.

By using VERI, you are agreeing to our

and

FGFR3 Y373C FGFR3 Y373C	Urothelial Cancer Urothelial Cancer	BGJ398 Sensitive: C3 – Early Trials BGJ398 Sensitive : C3
FGFR3 Y373C FGFR3 Y373C	Urothelial Cancer Urothelial Cancer	erdafitinib Sensitive: C3 – Early Trials erdafitinib Sensitive : C3
FGFR3 Y373C FGFR3 Y373C	Urothelial Cancer Urothelial Cancer	FGFR2 inhibitor Resistant: C3 – Early Trials FGFR2 inhibitor Resistant : C3
FGFR3 Y373C FGFR3 Y373C	Urothelial Cancer Urothelial Cancer	FGFR3 inhibitor Resistant: C3 – Early Trials FGFR3 inhibitor Resistant : C3
FGFR3 Y373C FGFR3 Y373C	Multiple Myeloma Multiple Myeloma	TAS 120 Sensitive: D – Preclinical TAS 120 Sensitive : D
FGFR3 Y373C FGFR3 Y373C	Multiple Myeloma Multiple Myeloma	bortezomib Resistant: D – Preclinical bortezomib Resistant : D